Oxford BioDynamics PLC OBD appoints Iain McInnes to Advisory Board
October 30 2019 - 2:00AM
RNS Non-Regulatory
TIDMOBD
Oxford BioDynamics PLC
30 October 2019
30 October 2019
Oxford BioDynamics Plc
("OBD" or the "Company" and, together with its subsidiaries, the
"Group")
OBD to appoint Professor Iain McInnes to its Scientific Advisory
Board
Oxford BioDynamics Plc (AIM: OBD), a biotechnology company
focused on the discovery and development of epigenetic biomarkers
based on regulatory genome architecture, for use within the
pharmaceutical and biotechnology industry, announces the
appointment of Professor Iain McInnes to its Scientific Advisory
Board. Iain will apply his expertise and insight as the Company's
EpiSwitch(TM) technology continues to be adopted by leading
pharmaceutical and biotechnology companies.
Iain is currently the Director of the Institute of Infection,
Immunity, and Inflammation, Muirhead Professor of Medicine and
Professor of Rheumatology at the University of Glasgow. Iain is the
President of the European League against Rheumatism (EULAR). In May
of this year, he was recipient of The Carol Nachman prize for
rheumatology. (1) In December 2018, Iain was awarded a CBE for his
services to medicine. (2) Oxford BioDynamics has collaborated with
Professor McInnes and his teams on several successful research
projects since 2014.
Professor McInnes joins Professor Karol Sikora, Professor Jane
Mellor and Professor Lucien Peng-Jin Ooi on OBD's expanding
Scientific Advisory Board.
Christian Hoyer Millar, Chief Executive Officer of Oxford
BioDynamics, said:
"We are delighted to announce the appointment of Professor Iain
McInnes and to welcome him to the OBD team. Iain is an eminent
professor and an expert in inflammatory disease processes, a core
focus for us. His knowledge and experience will be hugely
beneficial, as we further collaborate with leading pharma, biotech
and research institutions."
Professor Iain McInnes, member of the Scientific Advisory Board,
commented:
"I have known OBD for many years now and am extremely impressed
with the predictive power of EpiSwitch(TM) to identify patients
with rheumatoid arthritis who would not respond adequately to
methotrexate, the anchor drug used in this disease. OBD's method of
stratifying patients could have a profound effect on clinical
practice in many disease areas therefore I am looking forward to
working closely with my Board colleagues and the OBD team to help
realise the full potential of the EpiSwitch(TM) platform."
For further details please contact:
Oxford BioDynamics Plc
Christian Hoyer Millar,
CEO
Paul Stockdale, CFO +44 (0)1865 518910
FTI Consulting
Financial Public Relations
Adviser
Brett Pollard
Natalie Garland-Collins +44 (0)20 3727 1000
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a
biotechnology company focused on the discovery and development of
epigenetic biomarkers for use within the pharmaceutical and
biotechnology industry.
The Company's award-winning, proprietary technology platform,
EpiSwitch(TM), aims to accelerate the drug discovery and
development process, improve the success rate of therapeutic
product development and take advantage of the increasing importance
of personalised medicine.
In particular, EpiSwitch(TM) can reduce time to market, failure
rates and the costs at every stage of drug discovery. Additionally,
the technology provides significant insights into disease
mechanisms for drug discovery and product re--positioning
programmes and enables the personalisation of therapeutics for
patients in the context of challenging pricing environments where
improved clinical outcomes are critical.
In April 2019, Oxford BioDynamics received the Queen's Award for
Enterprise: Innovation. The Queen's Awards for Enterprise are the
most prestigious awards for UK businesses.
Oxford BioDynamics is headquartered in the UK, and listed on the
London Stock Exchange's AIM under the ticker "OBD". For more
information please visit www.oxfordbiodynamics.com.
(1)
https://www.eular.org/sysModules/obxContent/files/www.eular.2015/1_42291DEB-50E5-49AE-5726D0FAAA83A7D4/eular_press_release_carol_nachman_prize_2019.pdf
(2)
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/768288/NY19_Queens_List_31_December_2018.pdf
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAUKUNRKAARUAA
(END) Dow Jones Newswires
October 30, 2019 03:00 ET (07:00 GMT)
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From May 2023 to May 2024